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Abstract
Background: Patients with palliative care needs do not access specialist palliative care services according to their needs. Clinical 
Nurse Specialists working across a variety of fields are playing an increasingly important role in the care of such patients, but there is 
limited knowledge of the extent to which their interventions are cost-effective.
Objectives: To present results from a systematic review of the international evidence on the costs, resource use and cost-
effectiveness of Clinical Nurse Specialist–led interventions for patients with palliative care needs, defined as seriously ill patients and 
those with advanced disease or frailty who are unlikely to be cured, recover or stabilize.
Design: Systematic review following PRISMA methodology.
Data sources: Medline, Embase, CINAHL and Cochrane Library up to 2015. Studies focusing on the outcomes of Clinical Nurse 
Specialist interventions for patients with palliative care needs, and including at least one economic outcome, were considered. The 
quality of studies was assessed using tools from the Joanna Briggs Institute.
Results: A total of 79 papers were included: 37 randomized controlled trials, 22 quasi-experimental studies, 7 service evaluations and 
other studies, and 13 economic analyses. The studies included a wide variety of interventions including clinical, support and education, 
as well as care coordination activities. The quality of the studies varied greatly.
Conclusion: Clinical Nurse Specialist interventions may be effective in reducing specific resource use such as hospitalizations/re-
hospitalizations/admissions, length of stay and health care costs. There is mixed evidence regarding their cost-effectiveness. Future 
studies should ensure that Clinical Nurse Specialists’ roles and activities are clearly described and evaluated.
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Review Article
What is already known about this topic?
•• Resource use and costs tend to increase for patients with advanced disease and at the end of life.
•• Palliative care improves quality of life while reducing health care costs.
•• It is difficult to assess the effectiveness of Clinical Nurse Specialists (CNSs) working as individual providers.
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Introduction
There is some evidence that specialist palliative care 
(SPC) improves quality of care and reduces health sys-
tem costs and resource utilization,1,2 but few who could 
benefit are likely to access SPC services (such as hos-
pice care).3 The Worldwide Palliative Care Alliance3 
estimated in 2014 that 20 million people require pallia-
tive care (PC) at the end of life, with another 20 million 
needing PC support earlier in the disease trajectory. 
Such patients may have their PC needs met to varying 
degrees by a variety of providers, but there is a lack of 
evidence about this, especially where multiple profes-
sionals are involved and among patients with conditions 
other than cancer.4
Clinical Nurse Specialists (CNSs) play an increasingly 
prominent role in the support of people with PC needs, 
even if they do not have the term ‘palliative care’ in their 
job description or role title. The CNS role as an expert in 
evidence-based nursing practice in various fields is inter-
nationally recognized, although there are a wide variety of 
professional titles in use.5 While there is no universally 
agreed definition of CNS, there is an international consen-
sus that CNSs are nurses who have additional education, 
preferably at degree level or beyond.6 An example of a 
widely accepted definition comes from the International 
Council of Nurses, which defines the nurse specialist as 
‘… a nurse prepared beyond the level of a nurse generalist 
and authorized to practice with advanced expertise in a 
nursing field. Specialist practice includes clinical, teach-
ing, administration, research and consultant roles’.7
The extent to which CNSs focus on any of the latter 
areas either singly or in combination varies greatly.8 
CNSs frequently work as part of multidisciplinary 
groups; this makes it difficult to evaluate their effective-
ness as individual providers. There is a risk that inter-
ventions that are difficult to evaluate such as those 
provided by CNSs may have less opportunities in the 
competition for resources compared to those with higher 
levels of evidence,9 meaning that patients with PC needs 
may be unable to access any potential benefits.
Interventions delivered by CNSs can be described as 
ranging across several levels, from single patient contacts 
or advice provided to another staff member, through short-
term involvement for multiple problems (such as provision 
of support and information at the time of diagnosis), and 
finally long-term involvement with patients with rapidly 
changing or deteriorating conditions.10 All interventions 
delivered by CNSs are complex,11 comprising several 
interacting components and with sensitivity to contextual 
conditions; this makes their evaluation challenging. 
Despite this, there is some existing research on CNS-led 
interventions in different settings and with a variety of 
patient groups showing evidence of clinical and cost-effec-
tiveness. For example, a systematic review of the effec-
tiveness and cost-effectiveness of CNS interventions in 
outpatient care settings shows reduced costs and resource 
use compared to usual care, together with consistent evi-
dence of improved patient outcomes and largely similar 
health care system outcomes.12 One evaluation of advanced 
nursing roles in 12 countries shows that CNSs improve 
access to services, reduce waiting times and, in some con-
texts, deliver quality of care equivalent to that provided by 
doctors, with high satisfaction rates among the patients 
and informal carers.6 However, there are no systematic 
reviews of the cost-effectiveness of CNS-led interventions 
for patients with PC needs despite calls for greater under-
standing of the contribution that CNSs may be able to 
make to the quality and delivery of PC at scale.13 Reasons 
for the lack of evidence relate in part to the conceptual 
challenges surrounding the assessment of cost-effective-
ness of interventions for PC populations.2
This article presents a systematic review of interna-
tional evidence on the costs, resource use and cost-effec-
tiveness of CNS-led interventions of different types for 
patients with PC needs.
What this paper adds?
•• CNSs have an important role in palliative care provision, but this is a role that is currently poorly recognized and not 
articulated.
•• CNS interventions are effective in reducing health care resource use such as admissions, re-hospitalization, length of stay 
and health care costs.
•• CNSs may have the potential to enhance quality at neutral or lower costs to health care system while enhancing or 
delivering similar clinical or patient-reported outcomes but that new studies are necessary that address characteristic 
methodological shortcomings.
Implications for practice, theory and research
•• The inclusion of CNSs in national strategies to improve palliative care and enable more people to benefit from a pallia-
tive care approach at all stages of illness is recommended
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Objectives
The objectives of the review were to
1. Examine the available international evidence on 
the cost or resource use of CNS-led interventions 
in patients with PC needs.
2. Examine the available international evidence on 
the cost-effectiveness of CNS-led interventions in 
patients with PC needs.
3. Describe the range of CNS-led interventions in 
patients with PC needs, within the identified inter-
national evidence
Methods
Protocol and registration
The protocol for this study was registered in the Prospero 
register of systematic reviews.
Eligibility criteria
Type of study. This review considered quantitative studies 
addressing cost-effectiveness of CNS interventions includ-
ing randomized controlled trials (RCTs), quasi-experi-
mental, before and after, prospective and retrospective 
cohort studies, case control studies, analytical cross-sec-
tional studies, service evaluations and economic analyses.
Type of participants. We included adult patients (>18 years) 
with a clinical diagnosis of a life-limiting or life-threaten-
ing illness, who were unlikely to be cured, recover or sta-
bilize;4 please see Box 1.
Type of interventions. For the purpose of this review, inter-
ventions led by CNS (e.g. the CNS had an autonomous 
and clearly defined role) were included. Studies in which 
the training or level of education of the nurse was not 
clear, or in which the nurse was part of a multidisciplinary 
team (and thus their specific role cannot be established), 
were excluded.
Type of outcomes. Economic outcomes included the fol-
lowing: (1) costs; (2) objective measures of health system 
utilization such as length of stay (LOS), hospitalizations/
readmissions or health resource use (e.g. medications); 
and (3) cost-effectiveness measures (e.g. incremental cost/
effectiveness ratios). In order for studies to be included, 
they had to have at least one economic outcome.
Exclusion criteria. Articles were excluded if they were writ-
ten in languages other than English or Spanish. Other 
exclusion criteria were as follows: studies published prior 
to 2000, unpublished or incomplete papers (e.g. confer-
ence abstracts or letters to the editor) and systematic 
reviews or descriptive articles; studies published that 
included interventions which were not directed exclusively 
to patients with advanced disease (e.g. if they also included 
a family member or carer). Interventions directed to chil-
dren were also excluded.
Information sources
A pilot search in Medline and CINAHL enabled identifica-
tion of possible terminology. Initially, a pilot search in 
Medline and CINAHL was undertaken to identify key 
terms with the guidance from a library expert. We also 
examined the search strategy employed in related system-
atic reviews2 and contacted key authors for their full lists 
of search terms. In addition, we compared our search terms 
with the Mesh terms taxonomy in PubMed (and their 
equivalents in other databases). A second-stage search 
applied the identified key words and index terms across 
the following databases:
Medline via OVID (1946 to October 2015);
Embase via OVID (1980 to October 2015);
CINAHL via EBSCO (1986 to October 5 2015);
The Cochrane Library via Wiley (October 2015).
Search
Three groups of words and their equivalents were com-
bined using OR within each group: (1) advanced disease 
(including palliative/terminal care/medicine or cata-
strophic/critical illness or hospice or neoplasm or aged or 
disease progression or terminally ill), (2) cost-effectiveness 
(including costs or economics or cost analysis or cost 
effective or cost benefit analysis or health care costs or 
patient readmission or LOS); and (3) Clinical Nurse 
Specialist (including advanced practice nursing or nurse 
practitioners or critical care nursing or nurse clinicians). 
Each group was combined again using the operator AND. 
Box 1. 
Specific diseases considered in this review included the 
following:
Cancer
Advanced heart, lung, renal or liver disease
Dementia, epilepsy and neurodegenerative diseases
HIV/AIDS
Arthritis
Diabetes and leg ulcers
Frail patients (e.g. living in nursing facilities or residential 
care homes)
Patients in the intensive care unit (ICU) who were 
chronically critically ill
Patients 60 years and older with a concomitant chronic 
medical condition
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All search strategies are presented in Supplementary 
Material Appendix 1.
Study selection
Study selection was conducted in two stages. First, all 
titles and abstracts were screened for relevance by at least 
two reviewers (N.S.-B. and J.S. or G.C.). Disagreement 
was resolved by consensus. Second, studies that met the 
inclusion criteria were obtained and read. Reasons for 
exclusion were documented. EndNote was used to man-
age references.
Data collection process and data items
Information was recorded in an Excel chart developed for 
this review. Data were extracted by a research assistant 
(N.S.-B.) and included the following: publication details 
(author, year), country, study design, disease, interven-
tions and nurse activities, nurse training, outcomes, results 
and conclusions.
Synthesis of results
A narrative approach to synthesis was selected because of 
the great variety of study designs and outcome measures. 
It was not possible to conduct a meta-analysis of cost and 
resource utilization findings; instead, we focused on 
understanding and displaying patterns across the body of 
research.2
Quality assessment
There is no universally validated scale to assess quality in 
quantitative studies, and there is little evidence that such 
scales improve the validity of conclusions drawn from sys-
tematic reviews. Most tools are scales or checklists.14 We 
carried out quality assessment using software from the 
Joanna Briggs Institute for evidence-based health care15 
(Supplementary Material Appendix 2). Two reviewers 
independently answered each question; any disagreement 
was resolved by consensus. While we did not exclude 
studies on the basis of our quality assessment, we provide 
detailed information about study quality within the paper 
and its appendices.
Results
Study selection
A total of 7731 papers were obtained from the initial 
database search (Figure 1). After adjusting for dupli-
cates, 5984 citations remained. Of these, 5749 studies 
were discarded after reading the title and/or abstract 
because they clearly did not meet the inclusion criteria. 
The full text of the remaining 235 articles was read and 
assessed for eligibility. Of which, 156 studies did not 
meet the inclusion criteria; the reasons for their exclu-
sion were documented. A total of 79 studies were 
included in this review.
Study characteristics
General characteristics. Around 60% of the studies were 
conducted in the United States and the United Kingdom 
(27 and 20 studies, respectively) (Figure 2(a)). The major-
ity of studies were conducted in patients with heart failure 
(HF)16–36 (26.6%) or cancer (25%)37–53 (Figure 2(b)). We 
found 13 papers reporting formal economic analyses (such 
as cost-effectiveness ratios),16,30,31,33,35,39,44,47,54–58 9 of 
which were based on RCTs16,30,31,35,39,47,54,57,58 and 4 of 
which were other type of studies.33,44,55,56 We describe this 
group of studies separately, given the objectives of this 
review. A further 37 papers reported RCTs where economic 
outcomes, such as costs or resource use, were included as part 
of a wider set of outcomes.18,19,23,24,26,27,29,34,37,38,41–43,45,49–52,59–77 
In all, 22 papers reported quasi-experimental 
studies20–22,25,28,32,36,40,46,53,78–89 and 7 reported service evalua-
tions or other types of studies17,48,90–94 (Figure 2(c)). A wide 
variety of terms were used to describe nurses’ titles (Figure 
2(d)), with the most common term being ‘nurse specialist’, 
employed by one-third of the studies.16–18,27,30,31,33–35,39,42,43,46, 
47,50,52,54,64–66,72,73,75,76,78,87
Interventions: type and setting. A wide variety of interventions 
were described. In general, interventions were complex and 
involved multiple interacting components (Figure 3).
Interventions in which the clinical component was pre-
dominant included activities directed to the diagnosis, 
treatment and control of the disease and were performed in 
hospitals, outpatient clinics or patients’ homes.
Some papers described interventions that were support-
ive. They sought to increase patients’ knowledge about 
their disease and its management, and at the same time 
aimed to give psychological/spiritual support.
The roles adopted by the CNSs were usually reported to 
be multiple, and in many cases included care coordination 
activities.
Table 1 shows the components of the interventions (e.g. 
nurses’ specific activities) in each of the included papers. 
It was not always clear what the specific activity involved. 
For example, use in the papers of general terms such as 
‘in-hospital care and self-care’,80 or ‘monitoring patient’s 
condition’,62 made it difficult to identify nurses’ specific 
activities. We found a wide range of activities reported, 
including clinical consultations (in hospitals, at home, spe-
cialist clinics or via the telephone), the request of follow-
up investigations, prescription or adjustment of 
medications, referrals to other agencies or staff, provision 
of support directed at overall well-being, and education to 
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enhance self-management, as well as administrative work 
and liaison and communication with other professionals.
General characteristics by study type
Economic studies (n = 13). A total of 13 economic papers 
were included. Three reported a modelling of economic 
data (observational studies).33,55,56 A further nine reported 
RCTs.16,30,31,35,39,47,54,57,58 The final paper reported a pro-
spective study.44 In general, studies compared usual care 
(e.g. care provided by doctor or care provided in hospi-
tals), with nurse specialist care (e.g. specialist clinic, home 
visit or telephone follow up). Two studies compared inter-
ventions with different amount of nurse involvement (e.g. 
high- vs low-level support).31,55 Table 2 shows the main 
characteristics of the economic studies, which are described 
in the following paragraphs.
Six cost-utility analyses analysing the cost per QALY 
gained were found.30,31,35,44,54,57 Three cost-effectiveness 
studies were included comparing the cost per gained 
health outcome (e.g. year survived,16 HBA1c levels55 and 
lipid-level reduction58). Beaver et al.39 and Koinberg 
et al.47 performed cost-minimization studies measuring 
and comparing input costs, and assuming outcomes to be 
equivalent. Finally, Stewart et al.33 and Iles et al.56 reported 
cost analyses.
Totally, 11 out of 13 studies reported costs from one-
third party/health care system perspective (e.g. only direct 
Figure 1. PRISMA flow diagram.
6 Palliative Medicine 00(0)
Figure 2. Characteristics of included studies: (a) studies by country (%), (b) studies by disease (%), (c) study designs (%) and (d) 
nurse title (%).
Cardiac diseases: include coronary artery disease, acute coronary syndromes and atrial fibrillation; chronic diseases: include multiple chronic diseases and 
severe disability; neurological diseases: include Parkinson’s disease, neurodegenerative diseases and epilepsy; APN: advanced nurse practitioner; APN: 
advanced practice nurse; other: includes project nurse, qualified cardiac nurse, oncology nurses, contact nurse, cancer nurse and cardiac trained nurse.
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costs were considered). Two studies included additional 
costs. Beaver et al.39 included indirect costs such as num-
ber of missing days at work and patient transportation 
costs. Ndosi et al.57 calculated costs from the perspectives 
of the NHS (clinic and NHS resources), health care (NHS 
plus out-of-pocket) and ‘societal perspective’ (including 
loss trough time off work). The way costs were calculated 
varied across studies.
RCTs (n = 37). A total of 37 RCTs were included. Most 
compared a specialist nurse intervention with standard 
care (e.g. physician-led care or usual care).18,27,29,34,41,43,49–
52,59,61–71,73–77 Four interventions described tele-monitoring 
or telephone follow up in patients with HF,19,23 colorectal 
cancer42 and chronic obstructive pulmonary disease 
(COPD).72 Bakitas et al.37,38 described a multicomponent 
educational intervention for patients with advanced can-
cer, Berkhof et al.60 evaluated the effects of an outpatient 
on-demand interventions for patients with COPD, while 
Cockayane et al.24 and Heisler et al.26 described novel 
interventions for patients with HF. Finally, King et al.45 
evaluated the effects of home-based chemotherapy given 
by CNSs to cancer patients.
Quasi-experimental studies (n = 22). In total, 2 out of 22 
papers described telephone/monitoring follow-up inter-
ventions for patients with cancer and HF, respectively.20,40 
One describes the impact of the Evercare managed care 
intervention led by CNSs on hospital use in a nursing 
home population.83 There was a broadly equivalent focus 
in terms of setting with regard to the studies: eight reported 
CNS-led interventions targeted at hospital patie
nts25,28,78,80,81,87–89 and nine reported CNS-led interventions 
in the community or care home, which included the fol-
lowing: transitional care, care management and self-care/
disease management interventions.21,22,32,36,79,82,84–86 Two 
studies focused on CNS-led follow-up clinics as part of a 
multidisciplinary management programme for patients 
with rectal cancer.46,53
Service evaluation and other type of studies (n = 7). Five stud-
ies reported outcomes of ‘before and after’ evaluations of 
Figure 3. Components of Clinical Nurse Specialist interventions.
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specialist nurse-led services, including home-based PC,91 
monitoring and taking care of intensive care unit (ICU)94 
and tracheostomy patients,92 and outpatient clinics for 
patients with HF17 or head and neck cancer.48 Comparison 
was characteristically made with patients acting as their 
own controls or with a different cohort of patients prior to 
the initiation of the intervention. The remaining two stud-
ies comprised a natural experiment using a pre–post design 
to evaluate the effect of a transitional care clinic for indi-
viduals discharged from a skilled nursing facility93 and a 
retrospective observational cohort study of the effects of a 
home-based cardiac surgery nurse practitioner interven-
tion on readmissions.90
Synthesis of results
Results by study type
RCT. A total of 17 RCTs did not report any significant 
difference between groups in terms of LOS, emergency 
department (ED) visits, number of days in the ICU, medica-
tion use or readmissions.19,24,26,37,38,42,43,49,52,60,63,67–69,71,72,75 
They examined a model of CNS-led disease management 
or self-management in HF,19,24,26 cardiac care,63,67,68,71 
COPD,60,72 cancer care37,38,42,43,49,52,75 or chronic diabe-
tes.69 Six studies examined a formal PC or supportive care 
model,26,37,38,42,43,52 and two examined the use of CNS-led 
tele-care or tele-monitoring.19,72
Nevertheless, 13 RCTs reported that CNS-led interven-
tions were effective in reducing specific economic out-
comes. Four RCTs reported reduction in doctors’ visits 
(GP or specialist visits),49,60,61,63 two reported reductions in 
ED visits,64,77 five reported reductions in hospital readmis-
sions18,29,34,62,64 and seven reported reductions in 
LOS.18,23,27,34,61,64,77 Two RCTs found that CNS-led inter-
ventions were effective at increasing the use or prescrip-
tion of medications.34,59
CNS-led interventions were found to be less expensive 
than usual care in 4 out of 20 studies reporting costs.29,41,64,65 
A further 2 of the 20 studies reporting costs found that 
CNS interventions were more expensive,70,74 although in 
each case, the potential for cost-effectiveness was noted 
due to other positive outcomes. For example, Strong 
et al.,74 in a trial of a nurse-led clinic for management of 
people with depression due to cancer, reported that it was 
potentially cost-effective due in terms of the increase in 
quality-adjusted life-years achieved, as well as achieving 
good feasibility and acceptability. In all, 14 studies found 
non-significant or inconclusive results regarding 
costs.19,43,45,50,51,59–62,66,69,73,75,76
Quasi-experimental studies. Readmissions were reduced 
in the intervention group in 10 out of 17 studies report-
ing this outcome:20,22,25,28,32,79,80,83,84,86 5 evaluated a dis-
ease management CNS-led intervention for patients with 
HF or cardiac disease,20,22,25,28,80 3 evaluated a transitional 
care model led by CNSs32,84,86 and 1 each evaluated a case 
management model – Evercare led by a CNS for long-term 
care residents83 and a CNS-led psychosocial support inter-
vention for patients with heart disease.79
LOS was also reduced in 8 out of 13 stud-
ies22,25,28,81,83,84,86,88 employing a similar range of care mod-
els, that is, disease management,25,28,81 case management83,88 
and transitional84,86 or home-based care.22 Three of these 
latter studies also reported that CNS-led interventions 
reduce costs of care.22,81,84 The CNS-led case management 
intervention in a long-term care population (Evercare) 
increased doctors’ visits (GP) to the long-term care facili-
ties at the same time as reducing transfers to hospital,83 
while two of the disease-management-directed CNS-led 
interventions for patients with HF similarly increased pre-
scription and use of medications among recipients.25,28 
Reynolds et al.89 found, in a study comparing hospital fol-
low-up care led by consultants with care led by Parkinson’s 
disease nurse specialists, that the intervention was signifi-
cantly more expensive compared to the control group.
Service evaluation and other type of studies. Of the seven 
studies included in this category, four showed statisti-
cally significant reductions in re-hospitalizations;48,90,91,93 
Lukas et al.91 and Park et al.93 also found that the CNS ser-
vices reduced LOS. Regarding medication use, one study 
reported an increase in the prescription of medicines on the 
intervention group after the introduction of a CNS clinic 
for HF patients,17 and one of the palliative and supportive 
care interventions enhanced chemotherapy treatment com-
pletion and reduced on treatment dose deviations.48 Two 
interventions reported a reduction in hospital91 and direct 
readmission costs.
Results of cost-effectiveness (economic 
evaluation studies) 
In total, 13 studies were identified that may be classed as 
formal health economic studies and in which there was a 
variety of evidence about cost-effectiveness. Most evi-
dence was from studies of HF nurse specialists or CNSs 
working with high-risk coronary heart disease patie
nts,16,30,31,33,35,58 although there were also some studies of 
CNS-led cancer care39,44,47 and of other conditions.54–57
In seven studies, there was clear evidence of cost-effec-
tiveness or improvement on health economic out-
comes,16,31,33,35,44,47,58 five of which considered 
interventions in heart disease or cardiac care patients: 
Adlbrecht et al.16 showed in Austria that the supporting 
home-based nursing care with specialist nurses was both 
cost-effective and cheaper than standard care for HF 
patients. The costs per year survived after discharge were 
significantly lower for the intervention group compared to 
usual care. In the United States, incorporating nurse case 
management of cardiovascular disease risk factors into 
primary care settings was shown to be similarly cost-effec-
tive.58 The annual incremental cost-effectiveness of NP 
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case management was US$26.03 per mg/dL and US$39.05 
per percent reduction in low-density lipoprotein choles-
terol (LDL-C).58 It is important to consider that this con-
clusion should be interpreted with caution since the results 
are given in terms of costs/lipid reduction, which is a risk 
factor and nor at disease per se. A cost-utility analysis in 
the United Kingdom showed that a nurse-led disease man-
agement programme for patients with heart disease was 
cost-effective, generating an additional QALY at an incre-
mental cost of £13,158 per QALY, compared to the control 
group.35 In England, an observational study showed that a 
specialist nurse home service improves quality of life and 
reduces readmissions in patients with congestive HF, while 
also reducing costs.33 In a large-scale multicentre trial in 
the Netherlands among patients with HF, offering basic 
support to patients with mild to moderate HF and intensive 
CNS support to patients with severe HF improved health 
outcomes at slightly higher costs.31
Finally, two studies of cancer care by CNSs also dem-
onstrated cost-effectiveness. These included a trial of a UK 
nurse-led follow-up clinic for patients with colorectal can-
cer44 and a 5-year follow-up study in Sweden of patients 
with breast cancer showing that CNS-led care was cheaper 
and led to similar outcomes compared to physician-led 
care (€495 vs € 630 per person, respectively).47
In four studies, cost-effectiveness was not demonstrated 
mainly because of methodological challenges. In the first 
of these, a study of nurse-led care compared to physician-
led care of patients with rheumatoid arthritis,57 CNS care 
was shown to be equivalent in terms of quality and in some 
cases cheaper. In the second study, home-based CNS fol-
low up of patients with HF in Sweden was shown to be 
significantly cheaper at 12 months than standard care, at 
equivalent clinical outcomes, although small number of 
patients made conclusions difficult to draw. In addition, 
costs per QALY were lower in the home care group but the 
difference did not reach statistical significance.30 In the 
third study of CNS-led care for patients with diabetes, 
CNS-led care generated a modest reduction in costs per 
quality-adjusted life-year gained compared to usual care, 
although statistical significance was not reached.54 Similar 
conclusions were reached in Australian study of CNS-led 
care for people with diabetes.55
The remaining two studies classified as economic ana-
lysers included a short-term cost-minimization study 
examining a telephone follow-up CNS-led intervention for 
patients with breast cancer in the United Kingdom39 and a 
cost analysis of effects of practice nurse-led care for 
chronic diseases.56 In both cases, the interventions were 
associated with higher costs compared to usual care 
although some patients preferred these care models.
Results of costs and resource use 
The most common economic outcomes reported were 
costs and readmission rates (Table 3). We found that CNS 
interventions may be effective in reducing health care 
costs (13 out of 46 studies reported statistical significant 
reduction16,22,29,30,41,47,57,64,65,81,84,90,91). Another 22 out of 46 
studies reported that the intervention increases costs, 
although the results were statistically significant in only 
six of them.35,39,56,70,74,89
Regarding resource use (Table 3), there is evidence that 
CNS interventions may be effective in reducing hospitali-
zations and/or readmissions (20 out of 46 papers showed 
statically significant reductions in this outcome, while the 
remaining 26 did not report significant levels or reported 
non-significant results). LOS was significantly reduced in 
17 out of 33 studies, and only 1 study showed that the 
intervention significantly increases LOS.36 The rest of the 
papers (15 out of 33) reported no significant levels or it 
was not clear.
There is insufficient evidence to demonstrate that CNS 
interventions lower days in the UCI or ED visits. Four stud-
ies reported UCI days, all of which showed non-significant 
changes between groups.37,38,62,92 Regarding ED visits, only 
3 out of 16 studies found that intervention group signifi-
cantly reduced this outcome,64,77,80 while the remaining 13 
showed no significant changes.37,38,42,49,52,68,71,81,82,85,87,91,93
There is also insufficient information to make conclu-
sions on the effect of doctors (general practitioners or 
specialist/consultant) and CNS visits in any setting (Table 
3). Of 15 studies describing the utilization of doctors/phy-
sicians as an outcome, only 4 reported a statistically sig-
nificant decrease in doctors’ visits in the intervention 
group: Berkhof et al.60 concluded that COPD patients in 
the intervention group visited GPs significantly less (but 
CNSs more) than those in the control group. McCorkle 
et al.,49 Davies et al.61 and Goldie et al.63 found that women 
in the control group visited their primary care providers 
less often compared to those in the intervention group. 
However, another study found opposing results,83 and oth-
ers were inconclusive43,47,56,73 or reported non-significant 
results.42,69,71,75,85,87 There was a lack of evidence regarding 
CNS visits. Of 4 studies examining the latter, one con-
cluded that intervention group had significantly more vis-
its to the specialist nurse60 and the other three were 
inconclusive.43,47,56
There was some evidence with regard to referrals (e.g. 
to other health care professionals, health services or clin-
ics). Of 11 studies, 7 were inconclusive (showing non-sig-
nificant differences or not reporting significant 
levels.42,43,47,62,63,84,87 In contrast, four studies reported sig-
nificant differences regarding referrals. In the first, Naylor 
et al.85 concluded that the intervention reduced home 
health aides (p = 0.008) and physical therapy referrals 
(p = 0.001), although no significant changes were found for 
occupational therapy, social worker, vocational training, 
speech therapy and rehabilitation. In the second, an evalu-
ation of a CNS disease management model for HF, Lowery 
et al.28 concluded that the intervention significantly 
increased referrals to primary care and cardiology clinics. 
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Kane et al.83 found significant changes in referrals for 
physical, occupational and speech therapy, and podiatry, 
while Houweling et al.65 found that the percentage of 
patient referred back to the GP on the last months was sig-
nificantly higher in the CNS intervention group.
Five studies reported the use of laboratory test or 
images as an outcome, of which four did not find or report 
statistical significant changes.39,40,43,47 In an exception to 
this pattern, the fifth study53 found that CNS requested sig-
nificant more blood samples compared to surgeons when 
following up colorectal cancer patients.
Medication prescriptions were significantly increased 
in the intervention group in two studies,17,59 and medica-
tion uptake/use by patients was raised in another three 
studies.25,28,34 A study of a CNS-led supportive care inter-
vention for patients with head and neck cancer found that 
in the intervention group, there was a statistically signifi-
cant chemotherapy treatment completion and dose reduc-
tion compared to the control group.48 Four studies either 
did not find or did not report significant levels on this 
outcome.18,38,43,69
Table 3 summarizes the components of resource use: 
studies that reported a statistically significant effect 
towards the intervention group (or after the intervention in 
‘before and after’ studies) on specific outcomes were clas-
sified as effective (a total of 74 outcomes were reported as 
effective in the included studies). However, studies that 
reported a significant effect favouring the control group, or 
those reported non-significant outcomes, were classified 
as non-effective interventions (91 outcomes). Some of the 
studies did not report any significant level (or it was not 
clear after reading the article). In this case, papers were 
classified as not clear for that specific outcome (35 out-
comes). A small number of papers (5 out of 92) did not 
compare outcomes between groups, and reported a spe-
cific value in specific outcomes (e.g. cost of intervention); 
these were classified as descriptive.
Study quality
A summary of the quality of the included studies is pre-
sented in Figure 4(a)–(c). The RCTs scored well on most 
quality indicators including randomization procedures, 
statistical analysis, clear description of interventions and 
measurement of outcomes using reliable instruments. The 
quasi-experimental studies had greater variability in qual-
ity. Although, in general, statistical methods used were 
clearly described and outcomes were measured in a relia-
ble way for both groups, randomization procedures were 
not always described and it was not always clear whether 
an intention to treat analysis was performed or whether the 
groups were treated similarly other than the intervention. 
There was variation in RCTs and quasi- experimental stud-
ies on whether participants or allocators were blinded to 
treatment group allocation and whether control and 
intervention groups were comparable at entry to the trial. 
Economic evaluation studies were of good quality as well, 
having clear research questions and descriptions of the 
way costs were calculated. Weaknesses were lack of 
reporting of adjustments of cost for differential timing and 
variability in whether sensitivity analysis was performed.
The service evaluation and other studies had variable 
quality. They had some limitations regarding the descrip-
tion and inclusion in analysis of outcomes of people who 
withdrew from the study, strategies to identify and deal 
with confounding factors and sufficient length of follow 
up. Please refer to Supplementary Material Appendix 3 for 
more information about each specific study.
In general, because of the nature of the studies was 
reviewed, some criteria, such as concealing treatment 
groups and blinding participants, were not applicable to 
all the studies. In many cases, the CNS interventions 
were not well described, so it was difficult to evaluate 
Figure 4(a). Quality assessment of randomized controlled 
trials and quasi-experimental studies.
Questions:
Q1. Is the assignment to treatment groups truly random?
Q2. Are participants blinded to treatment allocation?
Q3. Is allocation to treatment groups concealed from the allocator?
Q4. Are the outcomes of people who withdrew described and included 
in the analysis?
Q5. Are those assessing the outcomes blind to the treatment alloca-
tion?
Q6. Are the control and treatment groups comparable at entry?
Q7. Are groups treated identically other than for the named interven-
tion?
Q8. Are outcomes measured in the same way for all groups?
Q9. Are outcomes measured in a reliable way?
Q10. Is appropriate statistical analysis used?
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whether the groups treated identically other than for the 
named intervention.
Discussion
Summary of evidence
This systematic review suggests that CNS interventions 
for patients with PC needs may be effective in reducing 
health care costs. In total, 13 out of 46 studies reported 
statistically significant reductions in costs, and 6 con-
cluded that the intervention significantly increased costs. 
However, many of the studies were limited in terms of the 
length of follow-up. We therefore know little about the 
long-term cost implications: even if costs are increased 
short term by a CNS intervention, CNS-led care may lead 
to health care costs being off-set over time. This may be 
due to a decrease in preventable events and better satisfac-
tion/quality of care experience; greater access to treatment/
care. Moreover, the methodology used to calculate costs in 
each study was different and often not clearly described, 
which might affect the final conclusion.
The evidence regarding resource use shows that CNS 
interventions may also be effective in reducing specific 
outcomes, specifically hospitalizations and re-hospitaliza-
tions/admissions, as well as LOS. Very few studies con-
cluded that the intervention significantly increased these 
outcomes, while an important proportion of them reported 
positive effects in reducing them. Similarly, 6 out of 10 
studies showed significant increase in prescription and 
usage of medications, suggesting that CNS interventions 
may enhance this outcome.
However, there is insufficient evidence to make conclu-
sions regarding ED and ICU visits, as well as doctor and 
nurse specialist visits, referrals and labs/exams/images.
Overall, the evidence regarding the cost-effectiveness 
of CNS interventions is inconclusive. Although 7 out of 13 
economic analyses reported some grade of cost-effective-
ness, 4 more were inconclusive and 2 more concluded that 
the intervention was more expensive.
Limitations
Although an attempt was made to include research relating 
to interventions exclusively performed by CNS for patients 
with PC needs, or in which CNS had a clear defined role, 
the boundaries between what the CNSs did and the input 
of other contributors were often hard to assess when decid-
ing about study inclusion. All the interventions described 
in the studies included in the review were complex: they 
had various interacting components, and frequently 
involved flexible activities on the part of the CNSs deliver-
ing care to patients.11
A variety of different interventions were reported in the 
included studies. Nevertheless, it was not always clear 
what the nurses’ roles (specific activities) were. For exam-
ple, when using words such as ‘patient assessment or care’, 
or when a CNS was introduced into an existing in-hospital 
service and specific tasks were not clearly described. In 
Figure 4(b). Quality assessment of service evaluation and 
other type of studies.
Questions:
Q1. Is the sample representative of patients in the population as a whole?
Q2. Are the patients at a similar point in the course of their condition/
illness?
Q3. Has bias been minimized in relation to selection of cases and 
controls?
Q4. Are confounding factors identified and strategies to deal with them 
stated?
Q5. Are outcomes assessed using objective criteria?
Q6. Is follow-up carried out over a sufficient time period?
Q7. Are the outcomes of people who withdrew described and included 
in the analysis?
Q8. Are outcomes measured in a reliable way?
Q9. Is appropriate statistical analysis used?
Figure 4(c). Quality assessment of economic evaluation studies.
Questions:
Q1. Is there a well-defined question?
Q2. Is there a comprehensive description of alternatives?
Q3. Are all important and relevant costs and outcomes for each alter-
native identified?
Q4. Has clinical effectiveness been established?
Q5. Are costs and outcomes measured accurately?
Q6. Are costs and outcomes valued credibly?
Q7. Are costs and outcomes adjusted for differential timing?
Q8. Is there an incremental analysis of costs and consequences?
Q9. Were sensitivity analyses conducted to investigate uncertainty in 
estimates of cost or consequences?
Q10. Do study results include all issues of concern to users?
Q11. Are the results generalizable to the setting of interest in the review?
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those papers in which the role was described in more 
detail, we found that the nurses’ activities could be mainly 
clinical, supportive or administrative/care coordination.
Although some authors developed their own inclusion 
criteria and definitions, we found an extensive variety of 
terms to describe a ‘CNS’ and a frequent lack of specification 
of their experience and training. This has made it challenging 
to consolidate evidence related to cost-effectiveness.
Moreover, we used a broad definition of patients with 
PC needs to reflect the reality of the range and complexity 
of patients with different diseases and different phases of 
illness who can benefit from PC. This gave rise to chal-
lenges in comparing and contrasting the studies. The appli-
cability of this evidence is further limited by the 
preponderance of research from resource rich countries 
(especially the United States and the United Kingdom), 
with diverse health care systems and funding.
The quality of included studies is variable. Many were 
not randomized and did not use a control group, affecting 
the validity and reliability of the results. In total, 46 (9 of 
which were economic analyses) out of the 92 included 
studies were RCTs, and they included multiple outcomes, 
patients and interventions. In some, the study population 
was small and approaches to statistical analysis were not 
clear; some did not report statistical significance.
Conclusion
This review provides an insight into the wide range and 
complexity of engagement of CNSs with patients with 
PC needs, in many different settings of care. However, it 
highlights important limitations in the evidence base that 
should be considered when developing further research, 
and when considering from a strategic planning perspec-
tive whether CNSs may be able to contribute to the pro-
vision of PC at scale, given the range and complexity of 
patients in need in contemporary health care systems102 
and the unlikelihood of being able to ensure that every 
person in need access a dedicated specialist PC 
service.103,104
Our review suggests that CNSs may have an important 
role in PC provision, but this is a role that is currently 
poorly recognized and rarely clearly articulated. In terms 
of cost and cost-effectiveness, it is clear that CNSs may 
have the potential to enhance quality at neutral or lower 
costs to health care system while enhancing or delivering 
similar clinical or patient-reported outcomes but that new 
studies are necessary that address characteristic methodo-
logical shortcomings. Future research of the CNS contri-
bution to PC should ensure that the CNSs’ expertise, 
training and specific intervention(s) are clearly described, 
focus on patient-perceived benefits and include longitudi-
nal study of economic impact. In the meanwhile, consid-
eration should be given to the inclusion of CNS-led care in 
national and international policies aimed at integrating PC 
into wider health care and thus enabling more people to 
benefit from a PC approach at all stages of illness.105
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